Tvardi Therapeutics Q3 net loss widens slightly less than expected

Overview

• US biopharma firm's Q3 net loss widened yr/yr but was slightly better than analyst expectations

• Company's research and development expenses increased due to higher clinical costs for TTI-101

• Tvardi expects key clinical milestones in 2027, pending IND clearance and additional funding

Outlook

• Company expects to report TTI-101 liver cancer study topline data in early Q1 2027

• Tvardi plans to initiate TTI-109 ulcerative colitis trial in 2027, pending IND clearance and funding

• Company anticipates existing cash will fund operations as planned into Q3 2027

Result Drivers

• HIGHER CLINICAL COSTS - Increased R&D expenses were primarily driven by higher clinical costs for TTI-101

• LOWER PROFESSIONAL FEES - Decrease in general and administrative expenses was mainly due to lower professional fees

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Tvardi Therapeutics, Inc. is $10.00, about 765.8% above its November 12 closing price of $1.16

Reuters Recommended Reads

• Nov 12 - SELLAS Life Sciences Q3 net loss widens on higher R&D costs

• Nov 12 - Assembly Biosciences Q3 net loss widens on increased R&D costs

• Nov 12 - Serina Therapeutics Q3 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)